OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer - Robson, ME; Tung, N; Conte, P (Ann Oncol, 2019)
et al.